Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy CHECKvacc in phase 1 clinical trial for triple negative breast cancer; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic and advanced gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. The company has a research collaboration with NeoImmuneTech to enhance cancer treatments. Imugene Limited is based in Sydney, Australia.
Metrics to compare | IMU | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMUPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.6x | −4.5x | −0.5x | |
PEG Ratio | 0.02 | −0.03 | 0.00 | |
Price/Book | 1.3x | 3.4x | 2.6x | |
Price / LTM Sales | −43.6x | 14.3x | 3.3x | |
Upside (Analyst Target) | - | 274.8% | 43.5% | |
Fair Value Upside | Unlock | −4.4% | 6.9% | Unlock |